Core Insights - Evaxion A/S is a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines and will present updates at various conferences in the latter half of 2025 [1][3][7] Company Updates - The company will engage with stakeholders and potential partners at multiple conferences across the US, Europe, and Asia to explore business partnerships and scientific collaborations [2][5] - Evaxion is particularly excited about presenting two-year clinical data for its personalized cancer vaccine EVX-01 at the ESMO congress in October 2025 [3][5] Conference Participation - Evaxion's conference schedule includes: - Vaccine Congress, September 7-10, Kyoto - HC Wainwright Global Investment Conference, September 8-10, New York - ESCMID Conference on vaccines, September 10-13, Lisbon - Lake Street Best Ideas Growth Conference, September 12, New York - HC Andersen seminar, September 18, Copenhagen - Vax On Vaccines: Present and future in oncology, October 1, Milan - BiotechX Europe, October 6-8, Basel - World Vaccine Congress Europe, October 14-16, Amsterdam - ESMO Congress 2025, October 17-21, Berlin - Society for Immunotherapy of Cancer (SITC) 2025, November 5-9, National Harbor - Vaccines Summit, November 13-15, Boston - NextGen Omics, November 13-14, London [5][6] Company Background - Evaxion utilizes its proprietary AI platform, AI-Immunology™, to develop novel immunotherapies targeting cancer, bacterial diseases, and viral infections, aiming to transform patient care with innovative treatment options [6][7]

Evaxion Biotech (EVAX) Q2 2025 Earnings Call August 14, 2025 08:30 AM ET Speaker0Hello, and welcome to Evaxion's Second Quarter twenty twenty five Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask the questions on the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised.To withdraw your question, please press star 1 again. I woul ...

Exhibit 99.1 EVAXION BIOTECH A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS | Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss for the Three and Six Months Ended June | Page | | --- | --- | | 30, 2025 and 2024 | 2 | | Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2025 and December 31, 2024 | 3 | | Unaudited Condensed Consolidated Interim Statements of Changes in Equity (Deficit) for the Six Months Ended June 30, ...

Core Insights - Evaxion A/S is progressing well with its AI-Immunology™ powered vaccine development, maintaining operational momentum and aiming to achieve 2025 milestones [2][5][11] Business Highlights - The company is on track to present two-year clinical data for its personalized cancer vaccine EVX-01 at the ESMO Congress on October 17, 2025, which is expected to attract potential partners [6][7] - Evaxion has received a grant from the Gates Foundation to explore a new sub-unit vaccine against polio, highlighting external interest in its AI-Immunology™ platform [9][10] - The R&D pipeline has been expanded with the addition of EVX-B4, targeting Group A Streptococcus, showcasing the platform's scalability [10] Financial Update - As of June 30, 2025, cash and cash equivalents increased to $14.7 million from $6.0 million at the end of 2024, providing a cash runway until mid-2026 [16] - Revenue for the second quarter of 2025 was $37 thousand, a decrease from $154 thousand in the same period last year, primarily due to changes in collaborative agreements [17] - The net loss for the second quarter of 2025 was $4.8 million, an improvement from a net loss of $6.2 million in the same period of 2024 [21] R&D and Clinical Trials - The phase 2 trial for EVX-01 has completed patient treatment, with three-year data expected in 2026 following a one-year trial extension [8][7] - The company is actively engaged in preclinical activities and has received recognition for its AI-Immunology™ platform, which is applicable to over 100 diseases [9][10] Business Development - Ongoing discussions with MSD regarding the EVX-B2 and EVX-B3 programs may lead to option exercises in the latter half of 2025, with potential milestone payments for Evaxion [11][12] - The company aims to secure at least two new partnership deals in 2025, despite challenges posed by current financial market conditions [13] Capital Structure - An agreement with the European Investment Bank (EIB) converted €3.5 million of debt into equity, improving equity by $4.1 million and enhancing financial flexibility [14][15]

COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, ope ...

Core Insights - Evaxion A/S will present two-year clinical efficacy data from its phase 2 trial of the personalized cancer vaccine EVX-01 at the ESMO Congress 2025 in Berlin [1][3] - EVX-01, developed using Evaxion's AI-Immunology™ platform, is currently being evaluated for advanced melanoma treatment, showing a 69% Overall Response Rate in interim data [2][4] - The phase 2 trial combines EVX-01 with MSD's KEYTRUDA® therapy, tailored to each patient's unique tumor profile [4][6] Company Overview - Evaxion is a clinical-stage TechBio company focused on AI-driven immunotherapies for cancer and infectious diseases [9] - The company utilizes its AI-Immunology™ platform to create personalized vaccines, aiming to enhance immune responses against tumors [6][9] - Evaxion's pipeline includes novel personalized vaccines for oncology and preclinical candidates for bacterial and viral diseases [9] Clinical Trial Details - The phase 2 trial of EVX-01 has shown promising results, with 67% of metastatic melanoma patients achieving objective clinical responses in earlier trials [7] - The upcoming presentation at ESMO will include data on T-cell responses and disease control over two years [5][6] - The trial emphasizes the correlation between AI predictions and immune responses, highlighting the platform's predictive capabilities [2][7]

Core Insights - Evaxion A/S has finalized an agreement with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity, enhancing its capital structure and financial flexibility [1][2][6] Group 1: Financial Impact - The conversion involves EIB purchasing ordinary Evaxion warrants at a price of $4.87, which represents a premium of 89% over the share price at market close yesterday [2][6] - This agreement immediately increases Evaxion's equity by $4.1 million (€3.5 million), while also substantially reducing overall liabilities and simplifying the balance sheet [2][6] Group 2: Management Commentary - The CFO of Evaxion, Thomas F. Schmidt, expressed satisfaction with the favorable terms of the agreement, highlighting its importance for cash flow and financial management [3]

Core Insights - Evaxion A/S announces key executive management changes to enhance value from its AI-Immunology™ platform and pipeline [1] - Christian Kanstrup steps down as CEO, with Dr. Birgitte Rønø appointed as interim CEO while a search for a new permanent CEO begins [2][5] - Thomas Schmidt is appointed as the permanent CFO, having previously served as interim CFO since November 2024 [3][4] Management Changes - The company is actively searching for a new CEO with a strong focus on business development and transformational leadership [5] - Dr. Rønø has been with Evaxion since 2017 and has significant experience in scientific and strategic roles [2] - Thomas Schmidt's financial expertise is expected to support the company's operations and leadership during this transition [4] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [7] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline for infectious diseases, addressing high unmet medical needs [7]

Core Insights - Evaxion A/S is developing a new preventive vaccine, EVX-B4, against Group A Streptococcus (GAS), which causes hundreds of millions of infections globally each year [1][2] - The AI-Immunology™ platform has been utilized to identify novel vaccine targets for GAS, enhancing the speed and effectiveness of target discovery and preclinical development [2][3] - The addition of EVX-B4 to the R&D pipeline aligns with Evaxion's strategy to increase partnership opportunities and out-licensing assets [4][9] Company Overview - Evaxion is a clinical-stage TechBio company focused on AI-driven vaccine development, with a pipeline that includes five infectious disease candidates and three cancer candidates [4][10] - The company aims to transform patient care by providing innovative immunotherapies for high unmet medical needs in cancer and infectious diseases [10] Industry Context - Group A Streptococcus infections can lead to severe health complications, including rheumatic heart disease and necrotizing fasciitis, with significant mortality rates if untreated [5][6] - The U.S. has seen an increase in invasive GAS disease rates since 2014, with an estimated 20,000 to 27,000 cases and 1,800 to 2,400 deaths annually [6] - Globally, rheumatic heart disease is a major cause of cardiovascular disease, with the World Health Organization estimating 470,000 new cases of acute rheumatic fever and 282,000 new cases of rheumatic heart disease each year [7]

Core Viewpoint - Evaxion A/S has received funding from the Gates Foundation to develop a new vaccine aimed at eradicating polio, utilizing its AI-Immunology™ platform to create innovative vaccine constructs [1][3][9] Company Overview - Evaxion A/S is a clinical-stage TechBio company focused on AI-powered vaccine development, particularly in the field of immunology [1][10] - The company employs its proprietary AI-Immunology™ platform to decode the human immune system and develop novel immunotherapies for various diseases [10] Project Details - The project will leverage Evaxion's AI-Immunology™ platform to identify and combine different antigens to combat the polio virus, with the goal of designing new vaccine constructs [3][4] - The funding from the Gates Foundation will cover the project's costs, allowing Evaxion to pursue this initiative without financial burden [3][4] Polio Context - Despite the availability of polio vaccines for decades, the disease remains a global health threat, with a risk of resurgence if not fully eradicated [2][8] - Polio primarily affects children under five, with one in 200 infections leading to irreversible paralysis, and a significant mortality rate among those paralyzed [7] Vaccine Innovation - Current polio vaccines rely on inactivated or attenuated viruses, which pose safety risks; the new approach aims to eliminate the use of live viruses in vaccine production [5][6] - The project seeks to create a safer and more effective alternative to existing polio vaccines, addressing unmet needs in the context of polio eradication efforts [6][8]